Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease

Shults, Clifford W.; Beal, M. Flint; Song, David; Fontaine, Deborah

doi:10.1016/j.expneurol.2004.05.003

Cited by 194 publications

(129 citation statements)

References 10 publications

Supporting

Mentioning

123

Contrasting

Unclassified

Order By: Relevance

“…Nine patients have dropped out and 28 have completed the trial. Plasma total CoQ 10 in 17 of the patients who completed the trial averaged 5.4 μg/ml, which is favorable compared with the adults in the McMaster University study receiving 1200 mg/d of ubiquinol, or the highest levels obtained in adults with Parkinson's disease (PD) receiving 2400 mg/d of generic CoQ 10 , or children with Down syndrome receiving a similar dose of ubiquinol to that used in this trial [27,28].…”

Section: Coq 10 and Idebenonementioning

confidence: 74%

Review of Clinical Trials for Mitochondrial Disorders: 1997–2012

Kerr

2013

Neurotherapeutics

View full text Add to dashboard Cite

Over the last 15 years, some 16 open and controlled clinical trials for potential treatments of mitochondrial diseases have been reported or are in progress, and are summarized and reviewed herein. These include trials of administering dichloroacetate (an activator of pyruvate dehydrogenase complex), arginine or citrulline (precursors of nitric oxide), coenzyme Q 10 (CoQ 10 ; part of the electron transport chain and an antioxidant), idebenone (a synthetic analogue of CoQ 10 ), EPI-743 (a novel oral potent 2-electron redox cycling agent), creatine (a precursor of phosphocreatine), combined administration (of creatine, α-lipoate, and CoQ 10 ), and exercise training (to increase muscle mitochondria). These trials have included patients with various mitochondrial disorders, a selected subcategory of mitochondrial disorders, or specific mitochondrial disorders (Leber hereditary optic neuropathy or mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes). The trial designs have varied from open-label/uncontrolled, openlabel/controlled, or double-blind/placebo-controlled/crossover. Primary outcomes have ranged from single, clinicallyrelevant scores to multiple measures. Eight of these trials have been well-controlled, completed trials. Of these only 1 (treatment with creatine) showed a significant change in primary outcomes, but this was not reproduced in 2 subsequent trials with creatine with different patients. One trial (idebenone treatment of Leber hereditary optic neuropathy) did not show significant improvement in the primary outcome, but there was significant improvement in a subgroup of patients. Despite the paucity of benefits found so far, well-controlled clinical trials are essential building blocks in the continuing search for more effective treatment of mitochondrial disease, and current trials based on information gained from these prior experiences are in progress. Because of difficulties in recruiting sufficient mitochondrial disease patients and the relatively large expense of conducting such trials, advantageous strategies include crossover designs (where possible), multicenter collaboration, and the selection of very few, clinically relevant, primary outcomes.

show abstract

Section: Coq 10 and Idebenonementioning

confidence: 74%

Review of Clinical Trials for Mitochondrial Disorders: 1997–2012

Kerr

2013

Neurotherapeutics

View full text Add to dashboard Cite

show abstract

“…Second, by adding Q10 or ubiquinone and especially its hydrolyzed form (i.e. ubiquinol or Q10-H2), the latter being characterized by a higher solubility and uptake via the intestinal tract (Hosoe, Kitano et al 2007), is one of the most important co-enzymes acting at complex II within the electrical transport chain of mitochondria (Shults, Bealc et al 2004). Third, by adding Q1 or NADH, i.e.…”

Section: Discussionmentioning

confidence: 99%

Faster Recovery after Exercise with Phytochemicals Aimed at Mitochondrial Energy Turnover - A Double Blind Randomized Placebo Control Study in College Female Soccer Players

Freye¹,

Strobel²

2015

IJPPE

View full text Add to dashboard Cite

Abstract:In order to replenish energy stores after exercise we developed a nutraceutical containing ingredients that precisely fuel the ATP generating mitochondria thus resulting in a faster recovery after workout. To test the working hypothesis 18 healthy female college soccer players (mean age 18) enrolled in a short but extreme workout on the treadmill for 12 min as demonstrated in their rise in lactic acid. The volunteers were given an energy drink containing Q10-H2 (ubiquinol), NADH (nicotinamideadenine-dinucleotide-hydride or Q1), ribose, eleutherosides B & E, Vit B2 & B3, passion flower and Vit E over a period of one week. Following a washout of 4 weeks a similar looking and tasting placebo solution was given in a double blind randomized crossover design. Heart rate recovery rate and systolic blood pressure demonstrated a significant faster return to base line than after placebo within the first 1-5 minutes following exercise. In addition, ATP regeneration capacity in leucocytes following washout of sodiumazide, a specific inhibitor at the mitochondrial electron transport complex V, was statistically higher (p < 0.05) in subjects after verum. The composition consisting of mitochondrial active substances, results in a higher synthesis rate of ATP, which coincided with a faster heart rate recovery rate after workout.

show abstract

“…Reported adverse gastrointestinal effects: nausea, upset stomach and vomiting, during clinical trials showed that, because no dose-response relationship was defined, the gastrointestinal effects are not related with the active ingredient [8,9]. 1,200 mgCoq10 taken daily produces no adverse side effects and levels as high as 3,000 mg/day were tested without adverse effects; although at this level there is no adequate product safety information [9][10][11]. Taken orally, Coq10 in a crystalline form is poorly absorbed.…”

Section: Pharmacokinetic Parameters Of Coq10mentioning

confidence: 99%

The Role of Coenzyme Q10 Supplementation with Statin Drug Use and Chronic Diseases

Peres¹,

Foss²,

Pereira³

2017

J Infect Dis Preve Med

View full text Add to dashboard Cite

Patients with chronic diseases exhibit a deficiency of Coenzyme Q10 (Coq10). Also, there is no doubt lowering cholesterol medication, statin drugs will "reduce the natural levels of CoQ10 in the body" Known to have antioxidant effects, Coq10 is essential for the proper functioning of adenine triphosphate (ATP) energy production in the cells. There is medical literature with positive recommendations for Coq10 supplementation with statin drugs. Unfortunately, because of controversial studies cited in the literature, there exists misinformation about the benefits of Coq10 supplementation in patients taking statins. Thus, the objective this mini-review is to discuss the beneficial role Coq10 supplementation provided to individuals taking statins and to encouraging doctors and health professionals to prescribe Coq10. Some of the negative feedback stems from the low bioavailability of oral Coq10 supplements. However, newer sublingual Coq10 supplementation formulas are much more absorbable. Additionally, solubilized CoQ10 in oil formulations show enhanced bioavailability. Coq10 protects the mitochondria and low levels of Coq10 produce mitochondrial dysfunction, reducing adenine triphosphate production. Various chronic diseases respond positively to Coq10 supplementation. Systematic reviews and clinical trials show persons taking statin medication have deficient levels of Coq10 and Coq10 supplementation decreases the negative side effects of statins. Unfortunately, many clinicians do not understand that the statin drugs block the rate-controlling enzyme of the mevalonate pathway, 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA reductase) whose detrimental consequences are broader than muscle-related adverse events. Providing significant improvement in endothelial function, Coq10 supplementation has been shown, also, to be efficacious in persons with heart failure. We argue in our medical communities; a perceptual shift is urgently needed, providing a positive approach to Coq10 supplementation with statin drug users and chronic disease patients.

show abstract

Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease

Cited by 194 publications

References 10 publications

Review of Clinical Trials for Mitochondrial Disorders: 1997–2012

Review of Clinical Trials for Mitochondrial Disorders: 1997–2012

Faster Recovery after Exercise with Phytochemicals Aimed at Mitochondrial Energy Turnover - A Double Blind Randomized Placebo Control Study in College Female Soccer Players

The Role of Coenzyme Q10 Supplementation with Statin Drug Use and Chronic Diseases

Contact Info

Product

Resources

About